Keywords
Breast Cancer, Medical diagnostic imaging, Fluorescent in situ hybridization (FISH) image, HER2 testing
Quantitative output variables
The proposed method found a total of 113 cells shown on the image. In these 113 cells 231 red and 51 green FISH signals were separately recognized. In figure 2, as it is shown the method is applied on another FISH image and the detected "red" and "green" FISH signals were 234 and 36 respectively.The HER2 amplification ratio for figure 1 was 0.22 (<2.2)which classifies as a HER2 negative. As can be seen in figure 2, since this ratio was 0.15 (<2.2), this example was also classified as a HER2 negative. Because of considerable stain debris and cell overlapping in a number of images, no analyzable cells were processed in some regions in sample images (for instance region 22 in figure 1 (d)). The sample images which are not noisy and have analyzable cells could be detected with over 99 percent accuracy in the acquired dataset.
References
[1] Andrew D Carothers. Counting, measuring, and mapping in fish-labelled cells: Sample size considerations and implications for automation. Cytometry Part A, 16(4):298–304, 1994.
[2] Charles E Geyer, John Forster, Deborah Lindquist, Stephen Chan, C Gilles Romieu, Tadeusz Pienkowski, Agnieszka Jagiello-Gruszfeld, John Crown, Arlene Chan, Bella Kaufman, et al. Lapatinib plus capecitabine for her2-positive advanced breast cancer. New England Journal of Medicine, 355(26):2733–2743, 2006.
[3] M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, D Craig Allred, Karen L Hagerty, Sunil Badve, Patrick L Fitzgibbons, Glenn Francis, Neil S Goldstein, Malcolm Hayes, et al. American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Archives of pathology & laboratory medicine, 134(7):e48–e72, 2010.
[4] Wedad M Hanna, Josef Ruschoff, Michael Bilous, Renata A Coudry, ¨ Mitch Dowsett, Robert Y Osamura, Fred´ erique Penault-Llorca, Marc ´ Van De Vijver, and Giuseppe Viale. Her2 in situ hybridization in breast cancer: clinical implications of polysomy 17 and genetic heterogeneity. Modern Pathology, 27(1):4–18, 2014.
[5] Jocelyne Jacquemier, Fred´ erique Spyratos, Benjamin Esterni, Marie- ´ Joelle Mozziconacci, Martine Antoine, Laurent Arnould, Sarab Lizard, ¨ Philippe Bertheau, Jacqueline Lehmann-Che, Cecile Blanc Fournier, ´ et al. Sish/cish or qpcr as alternative techniques to fish for determination of her2 amplification status on breast tumors core needle biopsies: a multicenter experience based on 840 cases. BMC cancer, 13(1):351, 2013.
[6] Feng Jiang and Ruth L Katz. Use of interphase fluorescence in situ hybridization as a powerful diagnostic tool in cytology. Diagnostic Molecular Pathology, 11(1):47–57, 2002.
[7] Bela Kajt ´ ar, G ´ abor M ´ ehes, Thomas L ´ orch, Linda De ¨ ak, Marika Kneifn ´ e,´ Donat Alp ´ ar, and L ´ aszl ´ o Pajor. Automated fluorescent in situ hybridiza- ´ tion (fish) analysis of t (9; 22)(q34; q11) in interphase nuclei. Cytometry Part A, 69(6):506–514, 2006.
[8] Klim McPherson, CaMa Steel, and JM Dixon. Breast cancerepidemiology, risk factors, and genetics. BMJ: British Medical Journal, 321(7261):624, 2000.
[9] Mark D Pegram, Gottfried Konecny, and Dennis J Slamon. The molecular and cellular biology of her2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer. In Advances in Breast Cancer Management, pages 57–75. Springer, 2000.
[10] Francesco Raimondo, Marios A Gavrielides, Georgia Karayannopoulou, Kleoniki Lyroudia, Ioannis Pitas, and Ioannis Kostopoulos. Automated evaluation of her-2/neu status in breast tissue from fluorescent in situ hybridization images. IEEE Transactions on Image Processing, 14(9):1288–1299, 2005.
[11] Xingwei Wang, Bin Zheng, Roy R Zhang, Shibo Li, Xiaodong Chen, John J Mulvihill, Xianglan Lu, Hui Pang, and Hong Liu. Automated analysis of fluorescent in situ hybridization (fish) labeled genetic biomarkers in assisting cervical cancer diagnosis. Technology in cancer research & treatment, 9(3):231–242, 2010.
[12] Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, Mitch Dowsett, Lisa M McShane, Kimberly H Allison, Donald C Allred, John MS Bartlett, Michael Bilous, Patrick Fitzgibbons, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology/college of american pathologists clinical practice guideline update. Journal of clinical oncology, 31(31):3997–4013, 2013.